SCHEDULE 13G/A: Medytox Inc. Discloses 3.4% Passive Stake in Evolus, Inc.
Beneficial Ownership Report
Medytox Inc., a South Korean company, has filed an amended Schedule 13G disclosing a 3.4% beneficial ownership stake in Evolus, Inc. as of December 31, 2024.
Summary
- Medytox Inc., a company organized under the laws of the Republic of Korea, has filed an Amendment No. 4 to Schedule 13G regarding its beneficial ownership in Evolus, Inc.
- As of December 31, 2024, Medytox Inc. beneficially owns 2,136,449 shares of Evolus, Inc.'s common stock.
- This ownership represents 3.4% of Evolus, Inc.'s outstanding common stock.
- The percentage calculation is based on a total of 63,321,493 shares of Common Stock outstanding as of November 1, 2024, as reported in Evolus, Inc.'s Quarterly Report Form 10-Q filed on November 6, 2024.
- Medytox Inc. holds sole voting power and sole dispositive power over all 2,136,449 shares.
- The filing certifies that the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of Evolus, Inc.
Sentiment
Score: 5
Explanation: The document is a factual disclosure of beneficial ownership, which is neutral in sentiment. It does not contain positive or negative financial performance data or strategic announcements.
Risks
- The filing explicitly states that the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer, indicating a passive investment stance by Medytox Inc.
Future Outlook
The document does not contain any forward-looking statements or guidance regarding the issuer's or reporting person's future operations or financial performance.
Management Comments
- "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11." (Certification by Hyunho Jung, CEO of Medytox Inc.)
Industry Context
This filing is a routine disclosure of a passive ownership stake by a South Korean pharmaceutical company (Medytox Inc.) in a U.S. aesthetics company (Evolus, Inc.). It does not provide specific insights into broader industry trends beyond confirming an existing investment relationship.
Stakeholder Impact
- Shareholders of Evolus, Inc. are informed of Medytox Inc.'s continued passive ownership stake, which remains below the 5% threshold for active investor reporting.
Key Dates
| Date | Description |
|---|---|
| 2024-11-01 | Date as of which Evolus, Inc. reported 63,321,493 shares of Common Stock outstanding in its Quarterly Report Form 10-Q. |
| 2024-11-06 | Date Evolus, Inc. filed its Quarterly Report Form 10-Q. |
| 2024-12-31 | Date of event which requires filing of this Schedule 13G statement (ownership position determination date). |
| 2025-02-06 | Date the Schedule 13G Amendment No. 4 was signed and filed by Medytox Inc. |
Keywords
Evolus Inc., Medytox Inc., Schedule 13G, Beneficial Ownership, Common Stock, SEC Filing, Passive Investment, Biotechnology, Pharmaceuticals, Aesthetics
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.